Article
A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Jan 2014
Rivero-Juarez Antonio, López-Cortés Luis F, Camacho Angela, Mira Jose A, Téllez Francisco, Marquez Manuel, Merino Dolores, Pineda Juan A, Rivero Antonio
Abstract excerpt
We designed a study to evaluate the efficacy of a 24-week treatment strategy in HIV/hepatitis C virus (HCV) genotype 3-coinfected patients achieving rapid virologic response for a first HCV treatment with pegylated interferon plus ribavirin (peg-IFN/RBV). Our results suggest that a shorter course of peg-IFN/RBV therapy may be sufficient in this population.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.